<DOC>
	<DOCNO>NCT00978822</DOCNO>
	<brief_summary>This study design assess rapidly safely Clevidipine use control high Blood Pressure patient subarachnoid hemorrhage type brain bleed happen weak balloon like structure one brain vessel . Control blood pressure high value prevent balloon rupture bleed rebleeding . The ultimate cure would shut aneurysm surgical procedure . Clevidipine drug lower blood pressure give vein continuous infusion . It short act drug important control labile blood pressure condition rapid change . This trial test rapid action check side effect possibly potential benefit .</brief_summary>
	<brief_title>Safety Efficacy Study Clevidipine Control Hypertension Patients Admitted With Aneurysmal Subarachnoid Hemorrhage</brief_title>
	<detailed_description>This single center , single-arm , non-blinded dose titration efficacy safety trial evaluate ability clevidipine , vascular-selective L-type calcium channel antagonist , rapidly control acute hypertension patient aneurysmal subarachnoid hemorrhage . At screen clinical neurological examination carry . For purpose study , acute hypertension define range SBP control within immediately prior initiation study drug . Approximately 20 patient acute A SAH enrol . Infusion study drug initiate soon ass patient arrive ER diagnosis make consent obtain . All eligible patient enrol receive clevidipine open label manner . Clevidipine infused initial rate 2.0 mg/h first 90 second . Thereafter , titration high infusion rate attempt need q90 second obtain target SBP range . Titration effect proceed double dose every 90 second , maximum 32.0 mg/h , desire effect ( SBP within target range ) attain . Clevidipine infusion may continue maximum 48 hour . Blood pressure ICP recording record q 5 minute . Assessment safety perform throughout treatment period 6 hour termination study drug .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Clevidipine</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<criteria>1 . Diagnosis SAH 2 . Presence unsecured aneurysm 3 . Patient age 18 80 year 4 . Hunt Hess grade &lt; 5 ( nonsedatedparalyzed pt ) 5 . Glasgow Coma scale &gt; 4 ( nonsedatedparalyzed pt ) 6 . BP prespecified upper limit set MD 7 . Patient receive pressor inotropes 8 . Patient receive IV antihypertensives 5 minute ( sodium nitroprusside infusion stop clevidipine start 9 . Patient give informed consent 1 . Patient &lt; 18 &gt; 80 year age 2 . Patient Traumatic SAH 3 . Patient Perimesencephalic SAH 4 . Hunt Hess grade 5 ( deeply comatose/ brain dead ) 5 . Glasgow Coma scale 3 4 ( deeply comatose/brain dead ) 6 . Patient pressor antihypertensives 5 minute 7 . SBP &lt; 90 mm Hg 8 . Heart rate &gt; 110 9 . Patient Left BBB 10 . Patient permanent ventricular pacemaker 11 . Known allergy dihydropyridines clevidipine 12 . Known allergy soy product , bean , egg egg products22 . Patients defective lipid metabolism pathologic hyperlipidemia lipid nephrosis 13 . Acute pancreatitis , accompany hyperlipidemia 14 . Severe aortic stenosis 15 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Subarachnoid hemorrhage</keyword>
	<keyword>Hypertension</keyword>
	<keyword>brain Aneurysm</keyword>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>antihypertensive</keyword>
	<keyword>calcium channel blocker</keyword>
	<keyword>infusion</keyword>
	<keyword>neurocritical care</keyword>
</DOC>